4D Molecular Therapeutics, Inc. FDMT

FDMT Company Overview

4D Molecular Therapeutics, Inc. (“4DMT”) is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for serious diseases with high unmet medical need. The company operates within the biotechnology and genetic medicine industries, with a primary emphasis on ophthalmology, pulmonology, and cardiology. Its core business model centers on discovering and developing proprietary AAV vectors designed to improve tissue targeting, durability, and therapeutic delivery compared with conventional gene therapy platforms. Revenue generation has historically been limited and primarily associated with collaboration agreements and financing activities, as the company remains in the clinical development stage rather than commercial operations.

The company’s strategic positioning is closely tied to its proprietary Therapeutic Vector Evolution platform, which is designed to create customized AAV capsids with enhanced specificity and reduced immunogenicity. 4DMT was founded in 2013 and later became publicly traded on Nasdaq under the ticker FDMT. Since inception, the company has expanded from platform development into a pipeline of clinical and preclinical gene therapy candidates, particularly targeting inherited retinal diseases and pulmonary conditions. Public disclosures in SEC filings and investor presentations indicate that the company seeks to differentiate itself through targeted vector engineering and potentially lower dosing requirements relative to competing AAV-based therapies.